Wall Street Zen Upgrades Shattuck Labs (NASDAQ:STTK) to “Buy”

Shattuck Labs (NASDAQ:STTK) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued on Saturday.

STTK has been the topic of a number of other reports. TD Cowen restated a “buy” rating on shares of Shattuck Labs in a report on Friday, March 6th. HC Wainwright raised shares of Shattuck Labs from a “neutral” rating to a “buy” rating and set a $6.00 target price for the company in a research note on Monday, December 1st. Wedbush increased their target price on Shattuck Labs from $4.00 to $8.00 and gave the stock an “outperform” rating in a report on Friday, March 6th. Citigroup lifted their price target on Shattuck Labs from $4.00 to $7.00 and gave the company a “neutral” rating in a research note on Friday, March 13th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Shattuck Labs in a report on Thursday, January 22nd. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.50.

Shattuck Labs Stock Performance

NASDAQ STTK opened at $6.02 on Friday. The business has a 50 day simple moving average of $4.73 and a 200 day simple moving average of $3.36. Shattuck Labs has a 52-week low of $0.69 and a 52-week high of $6.81. The stock has a market cap of $430.79 million, a price-to-earnings ratio of -7.82 and a beta of 1.55.

Shattuck Labs (NASDAQ:STTK) last announced its earnings results on Thursday, March 5th. The company reported ($0.12) EPS for the quarter, hitting the consensus estimate of ($0.12). The company had revenue of ($1.00) million for the quarter, compared to analyst estimates of $0.17 million. On average, analysts predict that Shattuck Labs will post -1.48 EPS for the current year.

Institutional Trading of Shattuck Labs

A number of institutional investors have recently made changes to their positions in the business. Turtle Creek Wealth Advisors LLC acquired a new position in Shattuck Labs during the third quarter worth $29,000. Virtu Financial LLC acquired a new stake in Shattuck Labs in the 3rd quarter valued at $38,000. AQR Capital Management LLC lifted its position in Shattuck Labs by 265.4% during the 1st quarter. AQR Capital Management LLC now owns 43,169 shares of the company’s stock worth $41,000 after buying an additional 31,355 shares in the last quarter. Qube Research & Technologies Ltd bought a new stake in Shattuck Labs during the 2nd quarter worth about $44,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Shattuck Labs during the 3rd quarter worth about $46,000. Institutional investors own 58.74% of the company’s stock.

About Shattuck Labs

Shattuck Labs, Inc (NASDAQ: STTK) is a clinical‐stage biotechnology company headquartered in Cambridge, Massachusetts. The company is focused on developing immunotherapeutic vaccines to prevent and treat substance use disorders, with an initial emphasis on opioids. Shattuck Labs employs a proprietary hapten‐carrier conjugate technology designed to generate high‐affinity drug‐specific antibodies that sequester target molecules in the bloodstream and reduce their passage across the blood‐brain barrier.

The company’s lead program targets fentanyl, a synthetic opioid responsible for a significant proportion of overdose fatalities.